Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Irritant potential of dithranol.

U F Haustein, I Lohrisch

    Dermatologica
    |January 1, 1986
    PubMed
    Summary

    Dithranol treatment for psoriasis can cause irritation. Researchers determined the minimal irritation dose (MID) and found that hyperreactive patients may benefit from starting therapy at their individually established MID.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis.

    Clinical pharmacology and therapeutics·2010
    Same author

    [Livedo racemosa with ulcerations. Cyclic therapy with iloprost infusions].

    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2007
    Same author

    [Centrifugal changing erythrosquamous plaque after a stay in West Africa].

    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2007
    Same author

    [Sports-induced infections--an overview].

    Wiener medizinische Wochenschrift (1946)·2003
    Same author

    Death due to pulmonary tuberculosis in progressive systemic sclerosis.

    Journal of the European Academy of Dermatology and Venereology : JEADV·2002
    Same author

    Erosion of psoriatic plaques: an uncommon side-effect of neoadjuvant 5-fluorouracil treatment of colon cancer.

    The British journal of dermatology·2002

    Area of Science:

    • Dermatology
    • Pharmacology
    • Inflammation

    Background:

    • Dithranol is a common topical treatment for psoriasis.
    • Individual responses to dithranol vary, necessitating personalized dosing strategies.
    • Understanding irritation thresholds is crucial for safe and effective dithranol therapy.

    Purpose of the Study:

    • To determine the minimal irritation dose (MID) and irritation dose 50 (ID50) for dithranol in patients with psoriasis.
    • To investigate dithranol hyperreactivity and its underlying mechanisms.
    • To provide recommendations for initiating dithranol therapy in hyperreactive individuals.

    Main Methods:

    • Open patch testing was used to determine the MID of dithranol in a 5% salicylic acid vaseline vehicle.
    • ID50 was calculated from the MID in control and psoriatic patient groups.
    • Dithranol hyperreactivity was assessed in patients with a history of adverse reactions.

    Main Results:

    • The ID50 values for controls (0.057%) and psoriatic patients (0.046%) were not statistically different due to inter-individual variability.
    • A subset of patients (13/20) exhibited decreased MID (0.01-0.02%), indicating hyperreactivity.
    • Hyperreactive patients showed blister formation at higher concentrations, with an irritant inflammatory mechanism suggested, excluding allergic contact dermatitis.

    Conclusions:

    • Individualized minimal irritation dose (MID) determination is essential for safe dithranol therapy, especially in hyperreactive psoriasis patients.
    • An irritant inflammatory mechanism, rather than allergic contact dermatitis, underlies dithranol hyperreactivity.
    • Therapy initiation with the patient's specific MID is recommended for hyperreactive cases to minimize adverse effects.

    Related Experiment Videos